

18 July 2024

Issue of Securities

Philadelphia PA and Phoenix AZ, 18 July 2024: Clinical dermatology company, Botanix Pharmaceuticals Ltd (ASX: BOT, “Botanix” or “the Company”), advises that it has issued securities to various employees and contractors pursuant to the Company’s Employee Awards Plan (“Plan”). The securities are subject to various vesting conditions and none of the securities are being issued to Directors or the CEO of the Company. The Company’s Plan was approved at the Company’s Annual General Meeting on 8 November 2023.

The securities were approved to be issued by the Board on 11 June 2024 and issued on 12 July 2024 as follows:

- (a) 23,000,000 BOTAAD performance rights;
- (b) 2,000,000 options exercisable at \$0.364 each expiring 12 July 2027;
- (c) 4,000,000 options exercisable at \$0.24 each expiring 12 July 2027; and
- (d) 10,000,000 options exercisable at \$0.24 each expiring 12 July 2028.

An Appendix 3G follows for immediate release.

This ASX announcement is authorised for release by the Board.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra*[™] for the treatment of primary axillary hyperhidrosis. *Sofdra*[™] is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H[^]CK

P: +61 423 139 163

haley@hck.digital